0000000000780923

AUTHOR

R. Pellegrino

showing 2 related works from this author

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB…

2022

Introduction: Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Body Composite Risk Score (LBCRS) and the Assessment Toolkit for DLB (AT-DLB). We aim to evaluate the reliability of these two questionnaires, and their ability to enhance the interpretation of the international consensus diagnostic criteria. Methods: LBCRS and AT-DLB were distributed to 135 Italian Neurological Centers for Cognitive Decline and Dementia (CDCDs), with the indication to administer them to all patients with dementia referred within the subsequent 3 months. We…

Lewy Body DiseaseClinical diagnosiDementia with Lewy bodieConsensus criteriaDementia with Lewy bodiesDermatologybehavioral disciplines and activitiesDiagnostic accuracyDiagnosis DifferentialAlzheimer DiseaseDiagnosismental disordersHumansReproducibility of ResultsDiagnostic toolkitGeneral MedicineClinical diagnosis; Cognitive impairment; Consensus criteria; Dementia; Dementia with Lewy bodies; Diagnostic accuracy; Diagnostic toolkitsClinical diagnosisnervous system diseasesSettore MED/26 - NEUROLOGIAPsychiatry and Mental healthCognitive impairmentItalyDifferentialDiagnostic toolkitsDementiaNeurology (clinical)
researchProduct